Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025

Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir

60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study

Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome

Privo Technologies reports progress in oral cancer trial

First patient in the Nordics treated with BioArctic and Eisai's Leqembi for early Alzheimer's disease

BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL

Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development

Lundbeck's bexicaserin granted Breakthrough Therapy Designation in China to treat seizures in severe rare epilepsies

Stealth BioTherapeutics launches Mito Assist Patient Support Program and partners with AnovoRx to distribute FORZINITY (elamipretide) injection

Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA

Sanofi's AlphaMedix meets all primary endpoints in phase 2 study in gastroenteropancreatic neuroendocrine tumours

Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS

Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation

Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio